Join Knight Therapeutics for Q3 2025 Results Discussion
Knight Therapeutics Inc. (TSX: GUD), a leading specialty pharmaceutical company, is preparing to share its financial performance for the third quarter of 2025. This conference call is an essential opportunity for investors and stakeholders to stay informed about Knight’s recent activities and financial health.
Conference Call Details
The upcoming call will take place on a Thursday morning in early November. Participants can expect key insights into the company's performance, strategic objectives, and future endeavors. It is an open invitation for all interested in learning more about Knight Therapeutics.
Important Information
Date: Thursday in early November
Time: 8:30 a.m. ET
Telephone Access: Participants can join by calling Toll Free: 1-888-699-1199 or International Line: 1-416-945-7677.
How to Access the Webcast
A live audio webcast will accompany the call. To listen, individuals are encouraged to visit the official Knight Therapeutics website. The webcast will provide broadcast access for media and the general public, but will be a listen-only session.
Replay Availability
For those who cannot attend the live event, an archived version will be available for approximately 30 days post-conference on the Knight Therapeutics website. This replay will allow everyone to catch up on the essential points discussed during the call.
About Knight Therapeutics Inc.
Headquartered in Montreal, Knight Therapeutics focuses on acquiring and commercializing pharmaceutical products primarily for Canada and Latin America. With a robust operational structure that includes subsidiaries operating in various sectors, Knight is positioned to leverage its strengths to meet market demands effectively.
Company Mission and Vision
Knight Therapeutics aims to enhance healthcare quality in its operational regions through innovative treatments and strategic partnerships. The company's dedication to quality is evident in its actions and product offerings.
Recent Developments
Recently, Knight Therapeutics has been expanding its portfolio and exploring new partnerships to bolster its market presence. This effort is crucial for sustaining growth and addressing the ever-evolving pharmaceutical landscape.
Investor Contact Information
For those interested in further inquiries, the following contacts are available:
Samira Sakhia, President & Chief Executive Officer
T: 514.484.4483 | Email: IR@knighttx.com
Arvind Utchanah, Chief Financial Officer
T: +598.2626.2344 | Email: IR@knighttx.com
Frequently Asked Questions
What is the date of the conference call?
The conference call will be held on a Thursday in early November 2025.
What time will the conference call start?
The call is scheduled to begin at 8:30 a.m. ET.
How can I access the conference call?
You can join the call by dialing the toll-free number or the international line provided during the announcement.
Will there be a replay available?
Yes, an archived replay of the conference call will be accessible for 30 days on the company's website.
What is the focus of Knight Therapeutics?
Knight Therapeutics focuses on acquiring and commercializing pharmaceutical products for Canada and Latin America.